Committee Will Sift Through 'Noise' Associated With Nuplazid Efficacy
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is concerned the change shown by Acadia's proposed Parkinson's psychosis product may not be clinically meaningful.